Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Strohmaier

Showing results (11-20 of 27) with videos related to

Pageof 3
Sort By:
Journal of Acquired Immune Deficiency Syndromes (1999)|June 30, 2012
Sustained efficacy and safety of raltegravir after 5 years of combination antiretroviral therapy as initial treatment of HIV-1 infection: final results of a randomized, controlled, phase II study (Protocol 004)Eduardo Gotuzzo, Martin Markowitz, Winai Ratanasuwan, et al.
Antiviral Therapy|October 29, 2014
Association between first-year virological response to raltegravir and long-term outcomes in treatment-experienced patients with HIV-1 infectionJoseph J Eron, David A Cooper, Roy T Steigbigel, et al.
Journal of Medicinal Chemistry|October 1, 1991
Topically active carbonic anhydrase inhibitors. 4. [(Hydroxyalkyl)sulfonyl]benzene and [(hydroxyalkyl)sulfonyl]thiophenesulfonamidesK L Shepard, S L Graham, R J Hudcosky, et al.
Antimicrobial Agents and Chemotherapy|December 31, 2008
Pharmacokinetics and safety of caspofungin in older infants and toddlersMichael Neely, Hasan S Jafri, Nita Seibel, et al.
Clinical Pharmacology and Therapeutics|August 24, 2007
Safety, tolerability, and pharmacokinetics of raltegravir after single and multiple doses in healthy subjectsM Iwamoto, L A Wenning, A S Petry, et al.
The Pediatric Infectious Disease Journal|September 26, 2009
Safety experience with caspofungin in pediatric patientsTheoklis Zaoutis, Thomas Lehrnbecher, Andreas H Groll, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|August 4, 2009
Sustained antiretroviral effect of raltegravir after 96 weeks of combination therapy in treatment-naive patients with HIV-1 infectionMartin Markowitz, Bach-Yen Nguyen, Eduardo Gotuzzo, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|May 8, 2009
A Multicenter, double-blind trial of a high-dose caspofungin treatment regimen versus a standard caspofungin treatment regimen for adult patients with invasive candidiasisRobert F Betts, Marcio Nucci, Deepak Talwar, et al.
Antimicrobial Agents and Chemotherapy|December 17, 2008
Pharmacokinetics and safety of caspofungin in neonates and infants less than 3 months of ageXavier Sáez-Llorens, Mercedes Macias, Padmanabha Maiya, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|March 23, 2010
Long-term efficacy and safety of the HIV integrase inhibitor raltegravir in patients with limited treatment options in a Phase II studyJose M Gatell, Christine Katlama, Beatriz Grinsztejn, et al.
Pageof 3

Showing results (11-20 of 27) with videos related to

Sort By:
Pageof 3
Journal of Acquired Immune Deficiency Syndromes (1999)|June 30, 2012
Sustained efficacy and safety of raltegravir after 5 years of combination antiretroviral therapy as initial treatment of HIV-1 infection: final results of a randomized, controlled, phase II study (Protocol 004)Eduardo Gotuzzo, Martin Markowitz, Winai Ratanasuwan, et al.
Antiviral Therapy|October 29, 2014
Association between first-year virological response to raltegravir and long-term outcomes in treatment-experienced patients with HIV-1 infectionJoseph J Eron, David A Cooper, Roy T Steigbigel, et al.
Journal of Medicinal Chemistry|October 1, 1991
Topically active carbonic anhydrase inhibitors. 4. [(Hydroxyalkyl)sulfonyl]benzene and [(hydroxyalkyl)sulfonyl]thiophenesulfonamidesK L Shepard, S L Graham, R J Hudcosky, et al.
Antimicrobial Agents and Chemotherapy|December 31, 2008
Pharmacokinetics and safety of caspofungin in older infants and toddlersMichael Neely, Hasan S Jafri, Nita Seibel, et al.
Clinical Pharmacology and Therapeutics|August 24, 2007
Safety, tolerability, and pharmacokinetics of raltegravir after single and multiple doses in healthy subjectsM Iwamoto, L A Wenning, A S Petry, et al.
The Pediatric Infectious Disease Journal|September 26, 2009
Safety experience with caspofungin in pediatric patientsTheoklis Zaoutis, Thomas Lehrnbecher, Andreas H Groll, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|August 4, 2009
Sustained antiretroviral effect of raltegravir after 96 weeks of combination therapy in treatment-naive patients with HIV-1 infectionMartin Markowitz, Bach-Yen Nguyen, Eduardo Gotuzzo, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|May 8, 2009
A Multicenter, double-blind trial of a high-dose caspofungin treatment regimen versus a standard caspofungin treatment regimen for adult patients with invasive candidiasisRobert F Betts, Marcio Nucci, Deepak Talwar, et al.
Antimicrobial Agents and Chemotherapy|December 17, 2008
Pharmacokinetics and safety of caspofungin in neonates and infants less than 3 months of ageXavier Sáez-Llorens, Mercedes Macias, Padmanabha Maiya, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|March 23, 2010
Long-term efficacy and safety of the HIV integrase inhibitor raltegravir in patients with limited treatment options in a Phase II studyJose M Gatell, Christine Katlama, Beatriz Grinsztejn, et al.
Pageof 3